Evidence map›Paper›PMID 26041662›Full record

ArticleMolecular neurobiology2015

Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease--Effects of Nanoencapsulated Neurotrophic Factors Administration.

C Requejo, J A Ruiz-Ortega, H Bengoetxea, A Garcia-Blanco, E Herrán, A Aristieta, M Igartua, L Ugedo, J L Pedraz, R M Hernández and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Enriched environment as a nonpharmacological neuroprotective strategy.Experimental biology and medicine (Maywood, N.J.) · 2023
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

C RequejoLaboratory of Clinical and Experimental Neuroscience (LaNCE), Department of Neuroscience, University of the Basque Country UPV/EHU, Leioa, Vizcaya, Spain, catalina.requejo@ehu.es.
J A Ruiz-Ortega
H Bengoetxea
A Garcia-Blanco
E Herrán
A Aristieta
M Igartua
L Ugedo
J L Pedraz
R M Hernández
J V Lafuente
University of the Basque Country · ESBiomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine · ESBioCruces Health research Institute · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Administration of various neurotrophic factors is a promising strategy against Parkinson's disease (PD). An intrastriatal infusion of 6-hydroxidopamine (6-OHDA) in rats is a suitable model to study PD. This work aims to describe stereological parameters regarding rostro-caudal gradient, in order to characterize the model and verify its suitability for elucidating the benefits of therapeutic strategies. Administration of 6-OHDA induced a reduction in tyrosine hidroxylase (TH) reactivity in the dorsolateral part of the striatum, being higher in the caudal section than in the rostral one. Loss of TH-positive neurons and axodendritic network was highly significant in the external third of substantia nigra (e-SN) in the 6-OHDA group versus the saline one. After the administration of nanospheres loaded with neurotrophic factors (NTF: vascular endothelial growth factor (VEGF) + glial cell line-derived neurotrophic factor (GDNF)), parkinsonized rats showed more TH-positive fibers than those of control groups; this recovery taking place chiefly in the rostral sections. Neuronal density and axodendritic network in e-SN was more significant than in the entire SN; the topographical analysis showed that the highest difference between NTF versus control group was attained in the middle section. A high number of bromodeoxyuridine (BrdU)-positive cells were found in sub- and periventricular areas in the group receiving NTF, where most of them co-expressed doublecortin. Measurements on the e-SN achieved more specific and significant results than in the entire SN. This difference in rostro-caudal gradients underpins the usefulness of a topological approach to the assessment of the lesion and therapeutic strategies. Findings confirmed the neurorestorative, neurogenic, and synergistic effects of VEGF+GDNF administration.

Indexed as

AnimalsCorpus StriatumDNA ReplicationDoublecortin Domain ProteinsDoublecortin ProteinDrug SynergismDrug Therapy, CombinationGlial Cell Line-Derived Neurotrophic FactorGlial Fibrillary Acidic ProteinInjections, IntralesionalMaleMicrotubule-Associated ProteinsNanocapsulesNerve Tissue ProteinsNeurogliaNeuronsDcx protein, ratDoublecortin Domain ProteinsDoublecortin ProteinGlial Cell Line-Derived Neurotrophic FactorGlial Fibrillary Acidic ProteinMicrotubule-Associated ProteinsNanocapsulesNerve Tissue ProteinsNeuropeptidesOxidopamineTyrosine 3-MonooxygenaseVascular Endothelial Growth Factor A

Identifiers

PMID26041662
OpenAlexW643968265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.